Filing Details

Accession Number:
0001298709-23-000023
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-12 17:17:31
Reporting Period:
2023-12-11
Accepted Time:
2023-12-12 17:17:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711279 Krystal Biotech Inc. KRYS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298709 S Krish Krishnan C/O Krystal Biotech, Inc.
2100 Wharton Street, Suite 701
Pittsburgh PA 15203
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-12-11 4,400 $104.41 1,654,938 No 4 S Direct
Common Stock Disposition 2023-12-11 6,263 $105.50 1,648,675 No 4 S Direct
Common Stock Disposition 2023-12-11 14,237 $106.11 1,634,438 No 4 S Direct
Common Stock Disposition 2023-12-11 100 $107.66 1,634,338 No 4 S Direct
Common Stock Disposition 2023-12-11 2,854 $104.26 1,596,352 No 4 S Indirect By Spouse
Common Stock Disposition 2023-12-11 4,541 $105.06 1,591,811 No 4 S Indirect By Spouse
Common Stock Disposition 2023-12-11 17,505 $106.04 1,574,306 No 4 S Indirect By Spouse
Common Stock Disposition 2023-12-11 100 $107.66 1,574,206 No 4 S Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 90,000 Indirect By Krishnan Spousal Trust
Common Stock 50,000 Indirect By Krishnan Family Trust
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
  2. The transaction was executed in multiple trades ranging from $103.9000 to $104.8800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. The transaction was executed in multiple trades ranging from $104.9000 to $105.8900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  4. The transaction was executed in multiple trades ranging from $105.9000 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  5. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 and will terminate on September 11, 2024 and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share.
  6. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.
  7. The transaction was executed in multiple trades ranging from $103.5600 to $104.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  8. Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.
  9. The transaction was executed in multiple trades ranging from $104.5600 to $105.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  10. The transaction was executed in multiple trades ranging from $105.5600 to $106.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  11. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.